logo
Micron's Big Q3 Drives Applied Materials' Bullish Outlook

Micron's Big Q3 Drives Applied Materials' Bullish Outlook

Globe and Mail3 days ago
Micron Technology's (NASDAQ: MU) recent fiscal Q3 2025 earnings are some of the best seen in the semiconductor industry over the past several months.
This is good news for one of the company's major suppliers, semiconductor equipment giant Applied Materials (NASDAQ: AMAT). Micron's earnings show trends that are likely to boost demand for Applied Materials' equipment.
Below is a deep dive into Micron's results and Applied's business that will demonstrate how the firm can benefit. We'll further examine Applied's positioning and valuation to understand if the stock represents a strong forward-looking investment opportunity.
Micron's Results Back Up Applied's Bullish Outlook
Micron crushed sales and adjusted earnings per share (EPS) estimates in its latest results. The memory chip maker's dynamic random-access memory (DRAM) sales were the driving force behind its great quarter. This was particularly true for its high-bandwidth memory (HBM) products, where sales grew by 50% in just one quarter. HBM is a type of DRAM that is particularly advanced and is ideal for AI data center applications.
Another very strong part of the report was that Micron increased its overall DRAM sales growth guidance for calendar 2025 from 'mid-teens' to " high-teens." The company also expects that HBM sales will increase 'significantly faster' than overall DRAM sales.
So, where does Applied Materials come into play?
Well, it just so happens that DRAM is one of Applied Materials' most important businesses. Last quarter, DRAM equipment sales made up 27% of the company's total revenue. Micron's strong DRAM sales mean they will likely need to buy more of Applied's equipment used to make it, which could greatly benefit Applied's overall sales.
Micron's results add significant weight to Applied's optimistic statements on DRAM demand. On May 15, Applied said it expects 'advanced DRAM' equipment sales to grow by 40% in 2025 as customers ' ramp investments ' in these technologies.
Advanced DRAM includes HBM but also DDR5. DDR5 is also used significantly in AI in data centers and attracts demand from high-performance PCs. Recent announcements from Micron support Applied's statements that investment in DDR5 will ramp up. In June, Micron said it would soon end production of DDR4, the predecessor to DDR5. Micron's information boosts confidence in what Applied has already shared. This positions the company for strong growth ahead.
AMAT: The Chip Advancement Enabler
Apart from the specific examples laid out above, one thing about Applied Materials is particularly important to understand. The advancements in its technology make the advancements in Micron's technology possible. As NVIDIA (NASDAQ: NVDA) and other end buyers want better Micron chips, Micron will need more advanced gear from Applied.
This is true for Micron and for other companies that manufacture different types of semiconductors.
Think Taiwan Semiconductor Manufacturing (NYSE: TSM).
Applied's position near the beginning of this supply chain is an advantage that makes it one of the best ways to gain exposure to the AI revolution. In the coming years, it can benefit from advances in all types of semiconductor chips. Many other companies focus on just one or a few areas.
This is also true for Applied, as the company makes equipment for various chip-making processes. It can offer customers a range of solutions that fit many of their needs. Meanwhile, ASML (NASDAQ: ASML), for example, focuses almost solely on lithography equipment.
Despite China, Applied Remains Set Up for Long-Term Success
Given export restrictions, Applied's exposure to China is important to discuss. Last quarter, 25% of Applied's revenues came from China. This is down from 43% from a year ago, largely due to export controls.
Still, the company notes that nearly all of its business in China involves 'mature' or less advanced technologies. Thus, the company's growth prospects based on technological advancement are not much tied to China, a positive sign for the long-term future.
As of the July 2 close, Applied Materials trades at a forward price-to-earnings multiple of 20x.
That compares to its three-year average figure of 19x. This suggests that based on next 12 months' estimates, the stock is neither greatly overvalued nor greatly undervalued.
Thus, expecting to pick up big returns from this stock quickly may be unrealistic. However, on a long-term horizon, the stock remains strongly positioned to appreciate. Years of upcoming chip advancement, which Applied's tech facilitates, can drive this.
Where Should You Invest $1,000 Right Now?
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Gilead Sciences Rallies 27.2% in Six Months: Buy or Sell the Stock?
Gilead Sciences Rallies 27.2% in Six Months: Buy or Sell the Stock?

Globe and Mail

time20 minutes ago

  • Globe and Mail

Gilead Sciences Rallies 27.2% in Six Months: Buy or Sell the Stock?

Shares of Gilead Sciences, Inc. GILD have gained 27.2% in the past six months against the industry 's decline of 2.2%. The stock has also outperformed the sector and the S&P 500 index in this time frame. Gilead Outperforms Industry, Sector & S&P 500 Index It has been an eventful year for GILD so far. The company recently obtained FDA approval for its twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, for the prevention of HIV. This groundbreaking injectable therapy marks the first and only twice-yearly pre-exposure prophylaxis (PrEP) option available in the United States. Let's delve further into GILD's strengths and weaknesses to analyze how to play the stock at present. Lenacapavir Approval Boosts GILD's HIV Franchise Gilead has a market-leading portfolio of HIV treatments. Flagship drug Biktarvy accounts for over 51% share of the treatment market in the United States and should maintain momentum. Descovy (FTC 200 mg/TAF 25 mg) for PrEP is also witnessing good uptake. It maintains over 40% market share in the PrEP market in the United States. The recent FDA approval of lenacapavir under the brand name Yeztugo solidifies GILD's HIV portfolio as its other prevention drug, Truvada, faces generic competition. At present, there are two FDA-approved daily oral medications for PrEP — Truvada and Descovy. As the first long-acting injectable PrEP administered just twice a year, Yeztugo addresses persistent barriers, such as challenges with daily oral PrEP, adherence, stigma and healthcare access, which have limited broader PrEP adoption. This approval also represents a paradigm shift in HIV prevention and is expected to catalyze uptake among populations that have historically been underserved by existing prevention tools. Yeztugo has a competitive advantage as it needs to be taken only twice a year, unlike daily oral pills, and addresses a broad population. The European Medicines Agency has also validated the Marketing Authorization Application for twice-yearly lenacapavir for HIV prevention. Livdelzi Strengthens GILD's Liver Disease Portfolio GILD's diverse portfolio also includes drugs for liver, hematology/oncology and inflammation/respiratory diseases. The FDA approval of seladelpar for the treatment of primary biliary cholangitis (PBC) has strengthened GILD's liver disease portfolio and validated its CymaBay acquisition. The drug's initial uptake is encouraging. The candidate was approved under the brand name Livdelzi. Gilead also recently received conditional marketing authorization from the European Commission for seladelpar for the treatment of PBC. Challenges for GILD's Oncology Business Gilead's oncology portfolio, comprising the Cell Therapy franchise and breast cancer drug Trodelvy, has diversified its overall business. However, the Cell Therapy franchise, comprising Yescarta and Tecartus, is currently under pressure due to competitive headwinds in the United States and Europe that are expected to continue in 2025. Breast cancer drug Trodelvy's sales were lower than expected in the first quarter due to inventory dynamics. Nonetheless, Gilead announced positive top-line results from the phase III ASCENT-03 study on Trodelvy, which showed highly statistically significant and clinically meaningful improvement in progression-free survival in patients with first-line metastatic triple-negative breast cancer (mTNBC) who are not candidates for checkpoint inhibitors. The potential launch of anito-cel in multiple myeloma and Trodelvy in first-line mTNBC in 2026 will strengthen the company's oncology business. GILD's Valuation and Estimate Revision According to the price/earnings ratio, GILD's shares currently trade at 13.62x forward earnings, lower than the large-cap pharma industry's average of 15.01X but higher than its mean of 10.52X. Earnings estimates for GILD have moved north in the past 60 days. The bottom-line estimate for 2025 has inched up to $7.92 from $7.91, while that for 2026 has improved to $8.48 from $8.39. Invest in GILD Large biotech companies are generally considered safe havens for investors interested in this sector as they are well-equipped to weather the uncertain macroenvironment. Gilead's efforts to constantly innovate its HIV portfolio should enable it to maintain growth amid competition from GSK plc GSK. The approval of Yeztugo for PrEP is a major boost for the company. GSK's HIV portfolio sales are being driven by strong patient demand for Cabenuva, Apretude and Dovato. GILD has also collaborated with Merck MRK to evaluate the investigational combination of islatravir and lenacapavir for the treatment of HIV. Gilead's strategic deals and acquisitions to diversify its business are encouraging. We recommend the stock to prospective investors, as we believe there is more room for growth following Yeztugo approval, even though Biktarvy sales are expected to be under pressure due to the redesign of Medicare Part D. Another positive factor for both prospective and existing investors is the company's attractive dividend yield. Gilead has been consistently increasing and paying out dividends. The company declared a quarterly dividend of $0.79 per share of common stock for the second quarter of 2025. Its strong cash position (as of March 31, 2025, GILD had $7.9 billion of cash, cash equivalents and marketable debt securities) indicates that the current yield of 2.83% is sustainable. Gilead presently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Zacks' Research Chief Picks Stock Most Likely to "At Least Double" Our experts have revealed their Top 5 recommendations with money-doubling potential – and Director of Research Sheraz Mian believes one is superior to the others. Of course, all our picks aren't winners but this one could far surpass earlier recommendations like Hims & Hers Health, which shot up +209%. See Our Top Stock to Double (Plus 4 Runners Up) >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report GSK PLC Sponsored ADR (GSK): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report

S&P/TSX composite down more than 100 points, U.S. stock markets also head lower
S&P/TSX composite down more than 100 points, U.S. stock markets also head lower

Winnipeg Free Press

time25 minutes ago

  • Winnipeg Free Press

S&P/TSX composite down more than 100 points, U.S. stock markets also head lower

TORONTO – Canada's main stock index fell more than 100 points, weighed down by losses in the technology sector, while U.S. stock markets also fell. The S&P/TSX composite index was down 129.73 points at 26,890.55. In New York, the Dow Jones industrial average was down 147.92 points at 44,258.44. The S&P 500 index was down 7.61 points at 6,222.37, while the Nasdaq composite was down 7.41 points at 20,405.11. The Canadian dollar traded for 73.10 cents US compared with 73.23 cents US on Monday. The August crude oil contract was up 15 cents US at US$68.08 per barrel. The August gold contract was down US$39.70 at US$3,303.10 an ounce. Monday Mornings The latest local business news and a lookahead to the coming week. This report by The Canadian Press was first published July 8, 2025. Companies in this story: (TSX:GSPTSE, TSX:CADUSD)

Cal-Maine Foods, Inc. Announces Release Date for Fourth Quarter and Fiscal 2025 Results
Cal-Maine Foods, Inc. Announces Release Date for Fourth Quarter and Fiscal 2025 Results

Globe and Mail

time35 minutes ago

  • Globe and Mail

Cal-Maine Foods, Inc. Announces Release Date for Fourth Quarter and Fiscal 2025 Results

Cal-Maine Foods, Inc. (NASDAQ: CALM) today announced that the Company will release its fourth quarter and fiscal 2025 financial results on Tuesday, July 22, 2025. A press release will be issued after the close of market trading. About Cal-Maine Foods Cal-Maine Foods, Inc. is primarily engaged in the production, packaging, marketing and distribution of fresh shell eggs, including conventional, cage-free, organic, brown, free-range, pasture-raised and nutritionally enhanced eggs, as well as a variety of egg products and prepared foods. The Company, which is headquartered in Ridgeland, Mississippi, is the largest producer and distributor of fresh shell eggs in the nation and sells most of its shell eggs throughout the majority of the United States.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store